Linus Health Launches First iPad-Based Brain Health Platform for Early Detection of Alzheimer’s and Other Dementias in Primary Care
Platform Empowers Providers with Digital, AI-Based Solutions to Help Them Identify and Intervene on Brain…
News
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET LEXINGTON, Mass., July 27,…
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the…
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif.,…
Biotech startup Shiru appoints Dr. Ranjani Varadan as Chief Scientific Officer
Formerly Impossible Foods’ VP of R&D and VP of Strategic Ingredients, Varadan assumes new role…
TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage…
Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function
CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage…
Akoya to Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
— Tumor control was achieved in four of ten evaluable patients with advanced solid tumors…
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic…
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent…
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it…
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July…
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with…
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis”…